ACHL:NSD-Achilles Therapeutics plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.02

Change

-0.21 (-4.96)%

Market Cap

USD 0.17B

Volume

0.09M

Avg Analyst Target

USD 23.00 (+472.14%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Achilles Therapeutics plc (ACHL) Stock Analysis:
Based on the Achilles Therapeutics plc stock forecasts from 1 analysts, the average analyst target price for Achilles Therapeutics plc is USD 23.00 over the next 12 months. Achilles Therapeutics plc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Achilles Therapeutics plc is Neutral, which is based on 2 positive signals and 2 negative signals. At the last closing, Achilles Therapeutics plc’s stock price was USD 4.02. Achilles Therapeutics plc’s stock price has changed by -0.03% over the past week, -0.64% over the past month and +0.00% over the last year.

About

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.55 (-3.76%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

-3.73 (-0.60%)

USD66.47B 9.89 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.23 (-0.97%)

USD58.90B 27.78 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-5.13 (-3.17%)

USD39.21B 5.08 5.67
BGNE BeiGene Ltd

+14.52 (+6.13%)

USD24.26B N/A N/A
SGEN Seagen Inc

+0.51 (+0.38%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

-0.36 (-1.04%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.66 (-1.65%)

USD17.17B 20.75 11.89

ETFs Containing ACHL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.76% 39% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.76% 39% F 18% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.17B 43% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.66 96% A 95% A
Price / Cash Flow Ratio -6.54 56% F 71% C-
EV/EBITDA 1.20 47% F 89% B+
Management Effectiveness  
Return on Equity -29.04% 79% C+ 36% F
Return on Invested Capital -23.20% 74% C 27% F
Return on Assets -17.19% 71% C- 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.64 85% B 82% B-
Short Percent 3.59% 57% F 42% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.